As PLD1 is a new target of vorinostat resistance, and combinational therapy of PLD1 inhibitor with vorinostat might be a potential therapeutic strategy against GBM tumorigenesis, it would be interesting to know whether it is possible to develop some biomarkers of therapeutic efficacy that could facilitate a more precise selection of the most suitable candidates for innovative combination therapy. This evidence concerns the gene PLD1 and glioblastoma.